ArticleCureus2025
Lupus Nephropathy in Mauritania: A Clinical and Longitudinal Study from the National Hospital Center of Nouakchott.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimLupus nephritis (LN) is a severe complication of systemic lupus erythematosus (SLE) with variable outcomes. This study aimed to describe the epidemiological, clinical, paraclinical, histopathological, and treatment outcomes of LN in the Nephrology Department of the National Hospital Center of Nouakchott.
methodsWe conducted a cross-sectional study over a 12-month period, from March 2023 to March 2024. All included patients had systemic lupus erythematosus complicated by nephropathy. We studied the epidemiological, clinical, paraclinical, histopathological, and evolutionary profile under treatment.
resultsTwenty-five patients were included; the mean age was 35.6 years, and the sex ratio (male/female) was 0.13. Extrarenal signs were dermatological in 12 patients and rheumatological in 10 patients. The mean proteinuria was 4.11±3.18 g/24 h (range: 0.38-14.5 g/24 h). The mean serum creatinine was 46.4±53.2 mg/L (range: 5-229 mg/L), and it was elevated in 16 patients (64%). Anti-dsDNA antibodies were positive in 16 patients, and antinuclear antibodies were positive in 13 patients. Histopathologically, classes IV and III were most frequently found in 11 and six patients, respectively; four patients had combined class IV and V, and five patients had isolated vascular and/or tubulointerstitial involvement. During the induction phase of treatment, 20 patients were on mycophenolate mofetil, while only one patient was on cyclophosphamide. Of the 22 patients with regular follow-up, three achieved complete remission, five had partial remission, nine progressed to end-stage renal disease, and five patients died.
conclusionsLupus nephritis often presents as severe proliferative forms, with an unpredictable course and a risk of progression to chronic kidney disease and death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.